By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Tarveda Therapeutics (Fomerly Known As Blend Therapeutics) 

134 Coolidge Avenue

Watertown  Massachusetts  02472  U.S.A.
Phone: 617-923-4100 Fax: 617-923-4101



Drug Delivery

Company News
Massachusetts' Tarveda Secures Another $30 Million to Push Cancer Drugs Into Clinic 2/2/2017 7:50:25 AM
Tarveda Provides Year-End Update And Outlines Milestones For 2017 1/5/2017 11:06:33 AM
Tarveda To Present At North American Neuroendocrine Tumor Society (NANETS) Symposium 9/29/2016 12:37:37 PM
Madrigal Wrangles Cancer Deal Worth $163 Million+ Out of Massachusetts' Tarveda 9/19/2016 5:57:16 AM
Tarveda Therapeutics Spins Out Placon to Pursue Development of Next-Gen Cytotoxic Oncology Drugs 3/23/2016 6:52:51 AM
Tarveda Therapeutics To Present At Cowen and Company 36th Annual Health Care Conference 2/29/2016 11:36:11 AM
Tarveda Therapeutics Appoints Oncology Drug Development Leader Leila Alland, M.D., As Chief Medical Officer 1/27/2016 8:37:54 AM
Blend Therapeutics Transforms into Tarveda Therapeutics and Bags $38 Million 1/27/2016 5:59:14 AM
Blend Therapeutics Presents Preclinical Data For Lead Pentarin™ Program, BTP-277, Demonstrating Specific And Potent Tumor Cell Targeting For Small-Cell Lung Cancer 4/21/2015 11:10:07 AM
Blend Therapeutics Presents Preclinical Data For Lead Candidate BTP-114 That Demonstrated Superiority To Cisplatin In Tumor Growth Inhibition 4/21/2015 11:09:07 AM